| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:DQP-997-74
CAS:2377187-09-0
Package:1removed
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Email: |
info@biorbyt.com |
| Products Intro: |
Product Name:DQP-997-74
CAS:2377187-09-0
|
|
| | DQP-997-74 Basic information |
| Product Name: | DQP-997-74 | | Synonyms: | DQP-997-74;1H-Pyrazole-1-butanoic acid, 5-(4-chlorophenyl)-3-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3-quinolinyl]-β,β-difluoro-4,5-dihydro-γ-oxo- | | CAS: | 2377187-09-0 | | MF: | C28H19Cl2F2N3O4 | | MW: | 570.37 | | EINECS: | | | Product Categories: | | | Mol File: | 2377187-09-0.mol |  |
| | DQP-997-74 Chemical Properties |
| density | 1.504±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | form | Solid | | pka | 3.031±0.21(predicted) | | color | Off-white to light yellow |
| | DQP-997-74 Usage And Synthesis |
| Uses | DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases[1]. | | References | [1] D'Erasmo MP, et al. Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor. ACS Chem Neurosci. 2023 Sep 6;14(17):3059-3076.. DOI:10.1021/acschemneuro.3c00181 |
| | DQP-997-74 Preparation Products And Raw materials |
|